Electronic Patient-Reported Outcomes Monitoring during lung cancer chemotherapy: a nested cohort within the PRO-TECT pragmatic trial (AFT-39)
Lung cancer is the third most commonly diagnosed cancer with more than 200,000 cases and the leading cause of cancer death with more than 130,000 fatalities nationally estimated for 2020.[1,2] Despite increasing survival rates,[1] more than 90% of lung cancer patients still report uncontrolled symptoms (e.g. dyspnea, cough, pain), which negatively impact their quality of life.[3] However, symptoms are commonly missed or underestimated by providers caring for cancer patients.[4] Therefore, systems to remotely monitor patient-reported outcomes (PROs) have been developed, with studies demonstrating improved detection of disease progression and reduced healthcare costs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Gita N. Mody, Angela M. Stover, Mian Wang, Bellinda L. King-Kallimanis, Jennifer Jansen, Sydney Henson, Arlene E. Chung, Mattias Jonsson, Antonia Bennet, Angela B. Smith, William A. Wood, Alison Deal, Brenda Ginos, Amylou C. Dueck, Deborah Schrag, Ethan B Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Cough | Healthcare Costs | Lung Cancer | Pain | Study